TY - JOUR
T1 - Arabinosyladenine monophosphate in genital herpes
T2 - A double-blind, placebo-controlled study
AU - Hatcher, Virgil A.
AU - Friedman-Kien, Alvin E.
AU - Marcus, Edwin L.
AU - Klein, Richard J.
N1 - Funding Information:
This study was supported by Warner-Lambert Pharmaceutical Company. We wish to thank Eileen Brady and Eugene DeStefano for their technical assistance.
PY - 1982/10
Y1 - 1982/10
N2 - A double-blind, placebo-controlled study was performed in 55 male patients with recurrent herpes simplex genitalis. The 29 patients who received topical arabinosyladenine monophosphate (ara-AMP) showed no significant difference in viral shedding, duration of pain, healing time or development of new lesions as compared to 26 placebo-treated patients. Ara-AMP was well-tolerated when topically applied. Serum neutralizing antibody titers did not change significantly during the acute and convalescent periods of the patient's recurrent HSG attacks. We conclude that ara-AMP, when applied topically as a 10% gel five times a day within 24 h of onset of recurrent HSG, does not influence the virologic and clinical evolution of the recurrent episode.
AB - A double-blind, placebo-controlled study was performed in 55 male patients with recurrent herpes simplex genitalis. The 29 patients who received topical arabinosyladenine monophosphate (ara-AMP) showed no significant difference in viral shedding, duration of pain, healing time or development of new lesions as compared to 26 placebo-treated patients. Ara-AMP was well-tolerated when topically applied. Serum neutralizing antibody titers did not change significantly during the acute and convalescent periods of the patient's recurrent HSG attacks. We conclude that ara-AMP, when applied topically as a 10% gel five times a day within 24 h of onset of recurrent HSG, does not influence the virologic and clinical evolution of the recurrent episode.
KW - arabinosyladenine monophosphate
KW - double-blind, placebo-controlled study
KW - genital herpes
UR - http://www.scopus.com/inward/record.url?scp=0020373740&partnerID=8YFLogxK
U2 - 10.1016/0166-3542(82)90051-1
DO - 10.1016/0166-3542(82)90051-1
M3 - Article
C2 - 6185089
AN - SCOPUS:0020373740
SN - 0166-3542
VL - 2
SP - 283
EP - 290
JO - Antiviral Research
JF - Antiviral Research
IS - 5
ER -